Bionik Laboratories (BNKL) 10-Q 14 Aug 18 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Jun. 30, 2018	Aug. 14, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,019
Document Fiscal Period Focus	Q1
Entity Registrant Name	Bionik Laboratories Corp.
Entity Central Index Key	1,508,381
Current Fiscal Year End Date	--03-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	BNKL
Entity Common Stock, Shares Outstanding		350,383,160

Condensed Consolidated Interim

Condensed Consolidated Interim Balance Sheets - USD ($)	Jun. 30, 2018	Mar. 31, 2018
Current
Cash and cash equivalents	$ 959,704	$ 507,311
Trade accounts receivable (net of allowance for doubtful accounts of $19,694; March 31, 2018 - $19,694)	370,180	212,730
Prepaid expenses and other receivables (Note 5)	485,438	433,655
Inventories (Note 6)	155,795	237,443
Due from related parties (Note 9(a)	18,547	18,897
Total Current Assets	1,989,664	1,410,036
Equipment (Note 7)	150,210	159,961
Technology and other Assets (Note 4)	4,635,666	4,706,719
Goodwill	22,308,275	22,308,275
Total Assets	29,083,815	28,584,991
Current
Accounts Payable (Notes 9(b) and 13)	736,141	724,673
Accrued liabilities (Notes 8 and 9(b))	1,127,364	1,529,505
Customer advances	800	800
Demand Loans (Note 8)	0	51,479
Convertible Loans (Note 8)	1,692,187	0
Conversion Feature on Convertible Loans (Note 8)	1,455,655	0
Deferred revenue	129,784	122,667
Shares to be issued, stock options and warrants (Notes 10,11 and 12)	0	5,692,853
Total Current Liabilities	5,141,931	8,121,977
Shareholders' Equity
Preferred Stock, par value $0.001; Authorized - 10,000,000; Special Voting Preferred Stock, par value $0.001; Authorized, issued and outstanding - 1 (March 31, 2018 – 1)	0	0
Common Shares, par value $0.001; Authorized - 500,000,000 (March 31, 2018 - 250,000,000); Issued and outstanding 247,873,882 and 41,271,880 Exchangeable Shares (March 31, 2018 - 205,328,106 and 44,271,880 Exchangeable Shares) (Note 10)	289,145	249,599
Additional paid-in capital	60,147,628	55,947,606
Deficit	(36,537,038)	(35,776,340)
Accumulated other comprehensive income	42,149	42,149
Total Shareholders' Equity	23,941,884	20,463,014
Total Liabilities and Shareholders' Equity	$ 29,083,815	$ 28,584,991

Condensed Consolidated Interim3

Condensed Consolidated Interim Balance Sheets [Parenthetical] - USD ($)	Jun. 30, 2018	Mar. 31, 2018
Allowance for Doubtful Accounts Receivable, Current	$ 19,694	$ 19,694
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	250,000,000
Common Stock, Shares, Issued	247,873,882	205,328,106
Common Stock, Shares, Outstanding	247,873,882	205,328,106
Common Stock, Other Shares, Issued	41,271,880	44,271,880
Common Stock, Other Shares, Outstanding	41,271,880	44,271,880
Special Voting Preferred Stock [Member]
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	1	1
Preferred Stock, Shares Issued	1	1
Preferred Stock, Shares Outstanding	1	1

Condensed Consolidated Interim4

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Sales	$ 501,333	$ 87,520
Cost of Sales	253,163	29,300
Gross Margin	248,170	58,220
Operating expenses
Sales and marketing	542,659	445,525
Research and development	676,743	685,909
General and administrative	979,479	627,606
Share-based compensation expense (Note 11)	595,412	251,048
Amortization (Note 4)	71,053	92,949
Depreciation (Note 7)	17,595	24,552
Total operating expenses	2,882,941	2,127,589
Other (income) expense
Foreign exchange	(41,134)	98,561
Accretion expense (Note 8)	134,251	0
Fair value adjustment (Note 8)	44,087	0
Gain on mark to market reevaluation	(2,048,697)	0
Other expense	37,420	72,588
Total other (income) expenses	(1,874,073)	171,149
Net loss and comprehensive loss for the period	$ (760,698)	$ (2,240,518)
Loss per share – basic	$ 0	$ (0.02)
Loss per share – diluted	$ 0	$ (0.02)
Weighted average number of shares outstanding – basic	257,509,141	96,959,284
Weighted average number of shares outstanding – diluted	257,509,141	96,959,284

Condensed Consolidated Interim5

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Deficiency) - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Deficit [Member]	Accumulated Other Comprehensive Income [Member]
Opening Balance at Mar. 31, 2017	$ 24,150,650	$ 0	$ 96,794	$ 45,088,171	$ (21,076,464)	$ 42,149
Opening Balance (in shares) at Mar. 31, 2017		1	96,794,443
Warrants exercised	1,125,038	$ 0	$ 5,000	1,120,038	0	0
Warrants exercised (in shares)		0	5,000,172
Share compensation expense	251,048	$ 0	$ 0	251,048	0	0
Share compensation expense (in shares)		0	0
Fair value of warrants on convertible loans	204,790	$ 0		204,790	0	0
Net loss for the period	(2,240,518)				(2,240,518)
Closing Balance at Jun. 30, 2017	23,491,008	$ 0	$ 101,794	46,664,047	(23,316,982)	42,149
Closing Balance (in shares) at Jun. 30, 2017		1	101,794,615
Opening Balance at Mar. 31, 2017	24,150,650	$ 0	$ 96,794	45,088,171	(21,076,464)	42,149
Opening Balance (in shares) at Mar. 31, 2017		1	96,794,443
Closing Balance at Mar. 31, 2018	20,463,014	$ 0	$ 249,599	55,947,606	(35,776,340)	42,149
Closing Balance (in shares) at Mar. 31, 2018		1	249,599,986
Opening Balance at Jun. 30, 2017	23,491,008	$ 0	$ 101,794	46,664,047	(23,316,982)	42,149
Opening Balance (in shares) at Jun. 30, 2017		1	101,794,615
Warrant down round feature	0	$ 0	$ 0	74,086	(74,086)	0
Share compensation expense	1,289,532			1,289,532
Share compensation expense (in shares)		0
Conversion of convertible notes	9,180,785	$ 0	$ 147,805	9,032,980	0	0
Conversion of convertible notes (in shares)		0	147,805,371
Fair value of warrants on convertible loans	343,389			343,389
Stock option and warrant reclassification	(2,845,557)	$ 0	$ 0	(2,845,557)	0	0
Beneficial conversion feature on convertible debt	1,389,129	0	0	1,389,129	0	0
Net loss for the period	(12,385,272)				(12,385,272)
Closing Balance at Mar. 31, 2018	20,463,014	$ 0	$ 249,599	55,947,606	(35,776,340)	42,149
Closing Balance (in shares) at Mar. 31, 2018		1	249,599,986
Share compensation expense	595,412	$ 0		595,412	0	0
Share compensation expense (in shares)		0	0
Conversion of convertible notes	2,470,622	$ 0	$ 39,546	2,431,076	0	0
Conversion of convertible notes (in shares)		0	39,545,776
Stock option and warrant reclassification	1,173,534	$ 0	$ 0	1,173,534	0	0
Net loss for the period	(760,698)				(760,698)
Closing Balance at Jun. 30, 2018	$ 23,941,884	$ 0	$ 289,145	$ 60,147,628	$ (36,537,038)	$ 42,149
Closing Balance (in shares) at Jun. 30, 2018		1	289,145,762

Condensed Consolidated Interim6

Condensed Consolidated Interim Statements of Cash Flows - USD ($)	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Operating activities
Net loss for the period	$ (760,698)	$ (2,240,518)
Adjustment for items not affecting cash
Depreciation	17,595	24,552
Amortization	71,053	92,949
Interest expense	36,702	72,766
Share based compensation expense	595,412	251,048
Accretion expense	134,251	0
Fair value adjustment	44,087	0
Gain on mark to market reevaluation	(2,048,697)	0
Allowance for doubtful accounts	(19,694)	0
Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities	(1,929,989)	(1,799,203)
Changes in non-cash working capital items
Accounts receivable	(137,756)	248,977
Prepaid expenses and other receivables	(51,783)	55,996
Due from related parties	350	(635)
Inventories	81,648	(27,297)
Accounts payable	11,468	104,648
Accrued liabilities	(402,141)	(5,428)
Customer advances	0	108,300
Deferred revenue	7,117	7,985
Net cash (used in) operating activities	(2,421,086)	(1,306,657)
Investing activities
Acquisition of equipment	(7,844)	(15,600)
Net cash (used in) investing activities	(7,844)	(15,600)
Financing activities
Proceeds from convertible loans	2,934,298	500,000
Proceeds on exercise of warrants	0	1,125,038
Repayment of Demand notes principal	(50,000)	0
Repayment of Promissory notes interest	(2,975)	0
Net cash provided by financing activities	2,881,323	1,625,038
Net increase in cash and cash equivalents for the period	452,393	302,781
Cash and cash equivalents, beginning of period	507,311	543,650
Cash and cash equivalents, end of period	$ 959,704	$ 846,431

NATURE OF OPERATIONS

NATURE OF OPERATIONS	3 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	1. NATURE OF OPERATIONS The Company and its Operations Bionik Laboratories Corp. (the “Company” or “Bionik”) was incorporated on January 8, 2010 in the State of Colorado as Strategic Dental Management Corp. On July 16, 2013, the Company changed its name to Drywave Technologies Inc. and its state of incorporation from Colorado to Delaware. Effective February 13, 2015, the Company changed its name to Bionik Laboratories Corp. and reduced the authorized number of shares of common stock from 200,000,000 to 150,000,000. Concurrently, the Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014. On February 26, 2015, the Company entered into a Share Exchange Agreement and related transactions whereby it acquired Bionik Laboratories Inc., a Canadian Corporation (“Bionik Canada”), and Bionik Canada issued 50,000,000 Exchangeable Shares, representing a 3.14 exchange ratio, for 100% of the then outstanding common shares of Bionik Canada (the “Merger”). The Exchangeable Shares are exchangeable at the option of the holder, each into one share of the common stock of the Company. In addition the Company issued one Special Preferred Voting Share (the “Special Preferred Share”) (Note 10). References to the Company refer to the Company and its wholly owned subsidiaries, Bionik Acquisition Inc. and Bionik Canada. On April 21, 2016, the Company acquired all of the outstanding shares and, accordingly, all assets and liabilities of Interactive Motion Technologies, Inc. (“IMT”), a Boston, Massachusetts-based global pioneer and leader in providing effective robotic products for neurorehabilitation, pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) dated March 1, 2016, with IMT, Hermano Igo Krebs, and Bionik Mergerco Inc., a Massachusetts corporation and the Company’s wholly owned subsidiary (Bionik Mergeco). The merger agreement provided for the merger of Bionik Mergerco with and into IMT, with IMT surviving the merger as the Company’s wholly owned subsidiary. In return for acquiring IMT, IMT shareholders received an aggregate of 23,650,000 shares of the Company’s common stock. On June 12, 2018, the Company approved the authorization of a common share capital increase to 500,000,000 from 250,000,000. The Company is a global pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders, specializing in designing, developing and commercializing cost-effective physical rehabilitation technologies, prosthetics, and assisted robotic products. The Company strives to innovate and build devices that can rehabilitate and improve an individual’s health, comfort, accessibility and quality of life through the use of advanced algorithms and sensing technologies that anticipate a user’s every move. These unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which contemplates continuation of the Company as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company’s principal offices are located at 483 Bay Street, N105, Toronto, Ontario, Canada M5G 2C9 and its U.S. address is 80 Coolidge Hill Road, Watertown, MA. USA 02472. Going Concern As at June 30, 2018, the Company had a working capital deficit of $3,152,267 (March 31, 2018 $6,711,941) and an accumulated deficit of $36,537,038 (March 31, 2018 $35,766,340) and the Company incurred a net loss and comprehensive loss of $760,698 for the three month period ended June 30, 2018 (June 30, 2017 – $2,240,518). There is no certainty that the Company will be successful in generating sufficient cash flow from operations or achieving and maintaining profitable operations in the future to enable it to meet its obligations as they come due, however the Company believes it has the support of its major shareholders who have provided convertible loans to meet the Company’s cash flow needs and to continue as a going concern. The Company hopes to raise sufficient cash in the next six months to meet the Company’s anticipated cash requirements for the 12 months thereafter. Sales of additional equity or equity-linked securities by the Company would result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required. In the event that the necessary additional financing is not obtained, the Company would reduce its discretionary overhead costs substantially or otherwise curtail operations. The Company expects the forgoing, or combination thereof, to meet the Company’s anticipated cash requirements for the next 12 months; however if these conditions are not achieved, this will raise significant doubt about the Company’s ability to continue as a going concern. The accompanying consolidated interim financial statements do not include any adjustments to reflect the possible effects of recoverability and reclassification of assets or amounts and classifications of liabilities that may result from the outcome of this uncertainty. All adjustments, consisting only of normal recurring items, considered necessary for fair presentation have been included in these condensed consolidated interim financial statements.

CHANGE IN ACCOUNTING POLICY

CHANGE IN ACCOUNTING POLICY	3 Months Ended
	Jun. 30, 2018
Disclosure Text Block [Abstract]
Accounting Changes and Error Corrections [Text Block]	2. CHANGE IN ACCOUNTING POLICY The FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260) Distinguishing Liabilities From Equity (Topic 480) Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments With Down Round Features II Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception , allows a financial instrument with a down-round feature to no longer automatically be classified as a liability solely based on the existence of the down-round provision. The update also means the instrument would not have to be accounted for as a derivative and be subject to an updated fair value measurement each reporting period. On consideration of the above factors, the Company elected to early adopt ASU 2017-11 on July 1, 2017. The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other organizations, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. The early adoption allows the Company to reduce the cost and complexity of updating the fair value measurement each reporting period and eliminate the unnecessary volatility in reported earnings created by the revaluation when the Company’s shares’ value changes. The Company presented the change in accounting policy through the retrospective application of the new accounting principle to all prior periods, as described in ASU No. 250-10-45-5, Accounting Changes and Error Corrections. The following financial statement line items for the periods indicated were affected by the change in accounting principle. Income statement Period ended June 30, 2017 As originally ‎ reported As adjusted Effect of change Sales $ 87,520 $ 87,520 $ - Cost of Sales 29,300 29,300 - Total operating expenses 2,127,589 2,127,589 - Total other expenses 175,953 171,149 (4,804 ) Net loss and comprehensive loss for the period (2,245,322 ) (2,240,518 ) 4,804 Statement of cash flows As at June 30 2017 As originally ‎ reported As adjusted Effect of change Net loss for period $ (2,245,322 ) $ (2,240,518 ) $ 4,804 Adjustment for items not affecting cash and changes in non-cash working capital items 938,665 933,861 (4,804 ) Net cash used in operating activities (1,306,657 ) (1,306,657 ) - Net cash used in investing activities (15,600 ) (15,600 ) - Net cash provided by financing activities 1,625,038 1,625,038 - Net increase in cash and cash equivalents for the period 302,781 302,781 - Cash and cash equivalents, beginning of period 543,650 543,650 - Cash and cash equivalents, end of period 846,431 846,431 -

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	3. SIGNIFICANT ACCOUNTING POLICIES Unaudited Condensed Consolidated Interim Financial Statements These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements of the Company and should be read in conjunction with those annual audited financial statements filed on Form 10-K for the year ended March 31, 2018. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. This is the first set of the Company’s unaudited condensed consolidated interim financial statements where ASU-2014-09 “Revenue from Contracts with Customers (Topic 606)” has been applied. The changes in accounting policies from those used in the Company’s unaudited condensed consolidated interim financial statements from the quarter ended June 30, 2018 are described below. Newly Adopted and Recently Issued Accounting Pronouncements Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying condensed consolidated interim financial statements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). The updated standard will replace most existing revenue recognition guidance in U.S. GAAP. The new standard introduces a five-step process to be followed in determining the amount and timing of revenue recognition. It also provides guidance on accounting for costs incurred to obtain or fulfill contracts with customers, and establishes disclosure requirements which are more extensive than those required under existing U.S. GAAP. The FASB has issued numerous amendments to ASU 2014-09 from August 2015 through January 2018, which provide supplemental and clarifying guidance, as well as amend the effective date of the new standard. ASU 2014-09, as amended, is effective for the Company in the interim period ended June 30, 2018. The standard permits the use of either the retrospective or modified retrospective (cumulative effect) transition method. The Company adopted the modified retrospective transition method The Company has adopted ASU-2014-01 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. As a result of the adoption of ASU-2014-09, the Company’s accounting policies have been updated. See “Revenue Recognition” below for these changes in accounting policies, as well as new disclosure requirements. The changes in accounting policies will also be reflected in the Company’s unaudited condensed consolidated interim financials statements as at the quarter ended June 30, 2018.” In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes,” which require that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015-17 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU-2015-17 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The updates make several modifications to Subtopic 825-10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 2017. The Company has adopted ASU-2016-01 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASU 2016-02 will have on the consolidated financial position and the consolidated results of operations. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU-2016-15 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. In January 2017, the FAS issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU2017-01 further states that when substantially all of the fair value of gross assets acquitted is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019. In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting (ASU 2107-9). The FASB issued the update to provide clarity and reduce the cost and complexity when applying guidance in Topic 718. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modifications accounting in Topic 718. ASU 2017-09 is effective for the Company in the interim period ended June 30, 2018. The Company has adopted ASU-2017-09 during the quarter ended June 30, 2018 and it did not have material effect on the consolidated financial position and the consolidated results of operations. Inventory Inventory is stated at the lower of cost or net realizable value. Cost is recorded at standard cost, on the first-in, first-out basis. Work-in-progress and finished goods consist of materials, labor and allocated overhead. Revenue Recognition The Company has adopted ASU-2014-09 with an initial application date of April 1, 2018. The updated accounting policies, the impact on the June 30, 2018 unaudited condensed consolidated interim financial statements and additional disclosures are detailed as follows: The Company determines revenue recognition through the following steps: a) identification of the contract with a customer; b) identification of the performance obligation in the contract; c) determination of the transaction price; d) allocation of the transaction price for the performance obligations in the contract; and e) recognition of revenue when the Company satisfies a performance obligation. Revenue is recognized when control of a product is transferred to a customer. Revenue is measured based on the consideration specified in a contract with a customer, net of returns and discounts. Accruals for sales returns are calculated based on the best estimate of the amount of product that will ultimately be returned by customers, reflecting historical experience and the magnitude of non-conforming inventory claims made by the customers that have either been approved or are pending review. Contract liabilities are recorded when cash payments are received or due in advance of the Company’s performance. In the comparative period, revenue was measured at the fair value of the consideration received or receivable, net of returns and discounts and was recognized when the risks and rewards of ownership has transferred to the customer. No revenue was recognized if there was significant uncertainties regarding recovery of the consideration due, the costs incurred or to be incurred could not be measured reliably, or there was continuing management involvement with the goods. Impact on the 2018 unaudited condensed consolidated interim financial statements ASU-2014-09 had no impact on the Company’s unaudited condensed consolidated interim statement of loss and comprehensive loss for the three month period ended June 30, 2018. Warranty Reserve and Deferred Warranty Revenue The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the balance sheet amounted to $75,065 and $64,957 at June 30, 2018 and March 31, 2018, respectively. The Company also sells extended warranties for additional periods beyond the standard warranty. Extended warranty revenue is deferred and recognized as revenue over the extended warranty period. The Company recognized $10,108 of expense related to the change in warranty reserves and warranty costs incurred and recorded as an expense in cost of goods sold during the three month period ended June 30, 2018 (June 30, 2017 $Nil). Foreign Currency Translation The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction. Use of Estimates The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The estimates are based on management’s best knowledge of current events and actions of the Company it may undertake in the future. Significant areas requiring the use of estimates relate to the valuation of inventory, revenue recognition, the useful life of equipment and intangible assets, impairment of goodwill and intangible assets. Actual results could differ from these estimates. Fair Value of Financial Instruments ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs, which are as observable as possible, and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, due from related parties, demand loans, and convertible loans approximate fair value because of the short period of time between the origination of such instruments, their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company has recognized shares to be issued, stock options and warrants, for which it did not as of March 31, 2018 have sufficient authorized share capital to issue, as a liability that is measured at fair value based on Level 1 inputs, for the component related to shares to be issued, and Level 3 inputs for the measurement of the stock options and warrants using a valuation model, as disclosed in Notes 11 & 12. This was reversed in the quarter ended June 30, 2018, when the Company’s authorized capital was increased from 250,000,000 to 500,000,000 and gain on mark to market valuation of $2,048,697 was recognized. The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the quarter ended June 30, 2018.

TECHNOLOGY AND OTHER ASSETS

TECHNOLOGY AND OTHER ASSETS	3 Months Ended
	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	4. TECHNOLOGY AND OTHER ASSETS The schedule below reflects the intangible assets acquired in the IMT acquisition on April 21, 2016 and the asset amortization period and expense for the three month period ended June 30, 2018 and the year ended March 31, 2018: Intangible Amortization Expense March Value at March Expense June Value at June assets acquired period (years) Value acquired 31, 2018 31, 2018 30, 2018 30, 2018 $ $ $ $ $ Patents and exclusive License 9.74 1,306,031 134,126 1,045,530 33,522 1,012,008 Trademark Indefinite 2,505,907 - 2,505,907 - 2,505,907 Customer relationships 10 1,431,680 143,206 1,153,543 35,792 1,117,751 Non-compete agreement 2 61,366 30,709 1,739 1,739 - Assembled Workforce 1 275,720 15,864 - - - 5,580,704 323,905 4,706,719 71,053 4,635,666 Amortization for the quarter ended June 30, 2017 was $92,949.

PREPAID EXPENSES AND OTHER RECE

PREPAID EXPENSES AND OTHER RECEIVABLES	3 Months Ended
	Jun. 30, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expense And Other Receivables [Text Block]	5. PREPAID EXPENSES AND OTHER RECEIVABLES June 30, 2018 March 31, 2018 $ $ Prepaid expenses and sundry receivables 73,987 86,957 Prepaid inventory 261,626 301,104 Prepaid insurance 136,113 36,497 Sales taxes receivable (i) 13,712 9,097 485,438 433,655 (i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES

INVENTORIES	3 Months Ended
	Jun. 30, 2018
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	6. INVENTORIES June 30, 2018 March 31, 2018 $ $ Raw materials 124,795 237,443 Work in Progress 31,000 - 155,795 237,443 During the three month period ended June 30, 2018, the Company expensed $237,000 in inventory as cost of goods sold (June 30, 2017 – $29,300).

EQUIPMENT

EQUIPMENT	3 Months Ended
	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	7. EQUIPMENT Equipment consisted of the following as at June 30, 2018 and March 31, 2018: June 30, 2018 March 31, 2018 Accumulated Accumulated Cost Depreciation Net Cost Depreciation Net $ $ $ $ $ $ Computers and electronics 264,349 227,977 36,372 256,505 223,750 32,755 Furniture and fixtures 36,795 28,481 8,314 36,795 28,051 8,744 Demonstration equipment 200,186 116,798 83,388 200,186 105,441 94,745 Manufacturing equipment 88,742 85,819 2,923 88,742 85,668 3,074 Tools and parts 11,422 6,020 5,402 11,422 5,741 5,681 Assets under capital lease 23,019 9,208 13,811 23,019 8,057 14,962 624,513 474,303 150,210 616,669 456,708 159,961 Equipment is recorded at cost less accumulated depreciation. Depreciation expense during the period ended June 30, 2018 was $17,595 (June 30, 2017 $24,552).

NOTES PAYABLE

NOTES PAYABLE	3 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	8. NOTES PAYABLE Demand Notes payable The Company had outstanding notes payable (“Notes”) of $Nil at June 30, 2018 ($51,479 March 31, 2018) which was acquired when the Company bought IMT on April 21, 2016. The Notes and interest were repaid during the quarter. Balance, March 31, 2018 $ 51,479 Accrued interest 1,496 Repayment 52,975 Balance, June 30, 2018 $ - Interest expense incurred on the Notes totaled $1,496 for the three month period ended June 30, 2018 (June 30, 2017 $2,341), which was included in accrued liabilities until it was paid off. Convertible Loans Payable During the quarter, the Company received loans totaling $2,965,971, which carry an interest rate of 1% per month of which $2,291,930 came from related parties. The loans and interest are convertible as of July 20, 2018 at a 10% discount to the 30 day weighted VWAP of the Company’s stock price. In the event the Company consummates a firm commitment or underwritten offering of its common stock by March 27, 2019, and the price per share thereof (the “ Offering Price The schedules below reflect the fair value and anti-dlution features of the convertible loans, which resulted in accretion expense of $134,251 and a fair value adjustment of $44,087 being expensed for the three months ended June 30, 2018 (June 30, 2017 - $Nil and $Nil). At issuance Conversion feature fair value At June 30, 2018 Principal Beneficial conversion Anti-dilution Fair value of debt Accretion expense Interest Ending balance Convertible promissory note $ 2,965,971 $ 368,936 $ 1,042,632 $ 1,554,403 $ 134,251 $ 3,533 $ 1,692,187 Conversion feature fair value Beneficial conversion Anti-dilution Total At Issuance $ 368,936 $ 1,042,632 $ 1,411,568 Fair value adjustment 60,304 (16,217 ) 44,087 Ending balance at June 30, 2018 $ 429,240 $ 1,026,415 $ 1,455,655

RELATED PARTY TRANSACTIONS AND

RELATED PARTY TRANSACTIONS AND BALANCES	3 Months Ended
	Jun. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	9. RELATED PARTY TRANSACTIONS AND BALANCES a) Due from related parties As at June 30, 2018, there was an outstanding loan to the Chief Technology Officer and director of the Company for $18,547 (March 31, 2018 – $18,897). The loan has an interest rate of 1% based on the Canada Revenue Agency’s prescribed rate for such advances and is denominated in Canadian dollars. During the period ended June 30, 2018, the Company accrued interest receivable in the amount of $59 (March 31, 2018 $707) and the remaining fluctuation in the balance from the prior year is due to changes in foreign exchange. b) Accounts payable and accrued liabilities As at June 30, 2018, $1,957 (March 31, 2018 $208,567) was owing to the CEO of the Company; $1,643 (March 31, 2018 $135,039) was owing to the Chief Technology Officer; and $920 (March 31, 2018 – $116,624) was owing to the Chief Financial Officer, all related to business expenses, all of which are included in accounts payable or accrued liabilities.

SHARE CAPITAL

SHARE CAPITAL	3 Months Ended
	Jun. 30, 2018
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	10. SHARE CAPITAL June 30, 2018 March 31, 2018 Number of Number of shares $ shares $ Exchangeable Shares: Balance beginning of year 44,271,880 44,273 47,909,336 47,910 Converted into common shares (a) (3,000,000 ) (3,000 ) (3,637,456 ) (3,637 ) Balance at the end of period 41,271,880 41,273 44,271,880 44,273 Common Shares Balance at beginning of the period 205,328,106 205,326 48,885,107 48,884 Shares issued to exchangeable shares 3,000,000 3,000 3,637,456 3,637 Shares issued on conversion of loans (b) 39,545,776 39,546 147,805,371 147,805 Warrants exercised - - 5,000,172 5,000 Balance at end of the period 247,873,882 247,872 205,328,106 205,326 TOTAL SHARES 289,145,762 289,145 249,599,986 249,599 a. During the three month period ended June 30, 2018, 3,000,000 exchangeable shares were exchanged on a 1 for 1 basis in accordance with their terms. (March 31, 2018 – 3,637,456). b. During the three month period ended June 30, 2018, 39,545,776 shares of common stock were issued once the Company increased its authorized shares of common stock from 250,000,000 to 500,000,000. These shares relate to convertible loans and interest that converted on March 31, 2018 and were recorded as a liability on March 31, 2018 until the shares were issued on June 12, 2018. The liability was reclassified at June 12, 2018 into equity by recording the original value of $2,470,622 of the shares to be issued, as well as the fair value of options and warrants at June 12, 2018 net of fair value of options issued in the period ended June 12, 2018 of $1,173,534, which was charged to equity and a $2,048,697 gain on the fair value reevaluation was recognized as other income in the Statement of Operations and Comprehensive Loss. Special Voting Preferred Share In connection with the Merger (Note 1), on February 26, 2015, the Company entered into a voting and exchange trust agreement (the “Trust Agreement”). Pursuant to the Trust Agreement, the Company issued one share of the Special Voting Preferred Stock, par value $0.001 per share, of the Company (the Special Voting Preferred Share”) to the Trustee, and the parties created a trust for the Trustee to hold the Special Voting Preferred Share for the benefit of the holders of the Exchangeable Shares (the “Beneficiaries”). Pursuant to the Trust Agreement, the Beneficiaries have voting rights in the Company equivalent to what they would have had, had they received shares of common stock in the same amount as the Exchangeable Shares held by the Beneficiaries. In connection with the Merger and the Trust Agreement, effective February 20, 2015, the Company filed a certificate of designation of the Special Voting Preferred Share (the “Special Voting Certificate of Designation”) with the Delaware Secretary of State. Pursuant to the Special Voting Certificate of Designation, one share of the Company’s blank check preferred stock was designated as the Special Voting Preferred Share. The Special Voting Preferred Share entitles the Trustee to exercise the number of votes equal to the number of Exchangeable Shares outstanding on a one-for-one basis during the term of the Trust Agreement. The Special Voting Preferred Share is not entitled to receive any dividends or to receive any assets of the Company upon liquidation, and is not convertible into common shares of the Company. The voting rights of the Special Voting Preferred Share will terminate pursuant to and in accordance with the Trust Agreement. The Special Voting Preferred Share will be automatically cancelled at such time as no Exchangeable Shares are held by a Beneficiary.

STOCK OPTIONS

STOCK OPTIONS	3 Months Ended
	Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	11. STOCK OPTIONS The purpose of the Company’s equity incentive plan, is to attract, retain and motivate persons of training, experience and leadership to the Company, including their directors, officers and employees, and to advance the interests of the Company by providing such persons with the opportunity, through share options, to acquire an increased proprietary interest in the Company. Options or other securities may be granted in respect of authorized and unissued shares, provided that the aggregate number of shares reserved for issuance upon the exercise of all options or other securities granted under the Plan shall not exceed 15% of the shares of common stock and Exchangeable Shares issued and outstanding (determined as of January 1 of each year). Optioned shares in respect of which options are not exercised shall be available for subsequent options. On November 24, 2015, the Company granted 650,000 options granted to employees that vest over three years at the anniversary date. The grant date fair value of the options was $694,384. During the year ended March 31, 2016, 250,000 options were cancelled and during the three month period ended June 30, 2018, $35,609 (June 30, 2017 $35,609) in stock compensation expense was recognized. On December 14, 2015, the Company granted 2,495,000 options to employees, directors and consultants that vest over three years at the anniversary date. The grant date fair value of the options was $1,260,437. During the years ended March 31, 2016, 2017 and 2018, 25,000 options, 40,000 options and 436,667 options, respectively, were cancelled and for the three month period ended June 30, 2018, $41,350 (June 30, 2017 $100,289) of stock compensation expense was recognized. On April 21, 2016, the Company granted 3,000,000 stock options to employees of Bionik, Inc., the Company’s wholly-owned subsidiary (formerly IMT) in exchange for 3,895,000 options that existed before the Company purchased IMT of which 1,000,000 have an exercise price of $0.25, 1,000,000 have an exercise price of $0.95 and 1,000,000 have an exercise price of $1.05. The grant date fair value of vested options was $2,582,890 and has been recorded as part of the original acquisition equation. The options are fully expensed, and $Nil (June 30, 2017 $10,169) has been recognized as stock compensation expense in the first quarter of 2018. On April 26, 2016, the Company granted 250,000 options to an employee with an exercise price of $1.00 that vest over three years at the anniversary date. The grant fair value was $213,750. During the quarter ended June 30, 2018, $17,813 (June 30, 2017- $17,813) was recognized as stock compensation expense. On August 8, 2016, the Company granted 750,000 options to an employee with an exercise price of $1.00 that vest over three years at the anniversary date. The grant fair value was $652,068. The employee left in April 2018 and 500,000 options that had not vested were cancelled and the remaining 250,000 options will expire in November 2018. During the quarter ended June 30, 2018, $18,113 (June 30, 2017 $54,339) of stock compensation expense was recognized. On February 6, 2017, the Company granted 400,000 options to an employee with an exercise price of $0.70 that vest over three years at the anniversary date. The grant fair value was $245,200. During the quarter ended June 30, 2018, $20,433 (June 30, 2017 $20,433) of stock compensation expense was recognized. On February 13, 2017, the Company granted 250,000 options to a consultant with an exercise price of $0.68 that vest over one and one-half years, every six months. The grant fair value was $148,750. During the quarter ended June 30, 2018, $12,396 (June 30, 2017 $12,396) of stock compensation expense was recognized. These options are now fully vested. On August 3, 2017, 1,500,000 options with an exercise price of $0.21 were granted to an executive officer, which vest equally over three future years. In addition, this executive officer was also granted up to 500,000 additional performance options based on meeting sales targets for the years ended March 31, 2018 and 2019. The grant value was $387,209 and $7,546 was expensed as stock compensation in the quarter. The executive left in April 2018 and all of these options were cancelled. On September 1, 2017, the Company granted 12,215,354 options with an exercise price of $0.161 equally to an executive officer and a consultant who is now the Chairman of the Company. Of such options, 2,035,892 have vested and 50% of the remaining options vest on performance goals being met and 50% vest over 5 years. The grant fair value was $1,832,304 and during the quarter ended June 30, 2018, $38,173 in stock compensation expense was recognized. On January 24, 2018, the Company granted 3,640,000 options with an exercise price of $0.155 to employees that vest equally on January 24, 2019, 2020 and 2021, The grant fair value was $491,036 and during the quarter ended June 30, 2018, $39,703 in stock compensation expense was recognized. On April 20, 2018, the Company granted to an executive officer, 6,000,000 options with an exercise price of $0.0649 that vest immediately with a 10-year expiry. The Options were valued using the Black-Scholes model and the following inputs were used: expected life of 10 years, expected volatility of 114% and a risk free rate of 1.59%. As these options fully vested on the grant date, $363,714 of stock based compensation was recognized during the quarter. On June 11, 2018, the Company granted to a newly-hired executive officer 750,000 options with an exercise price of $0.0462 that vest over three years from the anniversary of the grant and expire in 7 years. The Options were valued using the Black-Scholes model and the following inputs were used: expected life of 7 years, expected volatility of 114% and a risk free rate of 1.59%. The grant fair value was $30,341 and $562 of stock compensation expense was recognized in the quarter. During the quarter ended June 30, 2018, the Company recorded $595,412 in share-based compensation related to the vesting of stock options (June 30, 2017 $251,048). The following is a summary of stock options outstanding and exercisable as of June 30, 2018: Exercise Price ($) Number of Options Expiry Date Exercisable Options 0.165 154,134 April 1, 2021 154,134 0.23 94,368 June 20, 2021 94,368 0.23 1,981,728 July 1, 2021 1,981,728 0.23 141,557 February 17, 2022 141,557 1.22 400,000 November 24, 2022 266,667 1.00 1,936,667 December 14, 2022 1,633,333 0.95 111,937 March 28, 2023 111,937 1.05 433,027 March 28, 2023 433,027 1.00 250,000 April 26, 2023 166,667 1.00 250,000 August 8, 2023 250,000 0.70 400,000 February 6, 2024 133,333 0.68 250,000 February 13, 2024 250,000 0.95 31,620 March 3, 2024 31,620 1.05 122,324 March 3, 2024 122,324 0.95 6,324 March 14, 2024 6,324 1.05 24,465 March 14,2024 24,465 0.95 72,727 September 30, 2024 72,727 1.05 281,345 September 30, 2024 281,345 0.95 3,478 June 2, 2025 3,478 1.05 13,456 June 2, 2025 13,456 0.25 66,298 December 30, 2025 66,298 0.95 49,160 December 30, 2025 27,261 0.161 12,215,354 September 1, 2027 2,035,892 0.155 3,365,000 January 24, 2025 - 0.0649 6,000,000 April 19, 2028 6,000,000 0.0462 750,000 June 10, 2025 - 29,404,696 14,301,941 The weighted-average remaining contractual term of the outstanding options was 7.89 (March 31, 2018 – 5.81) and for the options that are exercisable the weighted average was 7.38 (March 31, 2018 – 5.70)

WARRANTS

WARRANTS	3 Months Ended
	Jun. 30, 2018
Warrants and Rights Note Disclosure [Abstract]
Shareholders Equity And Share Based Payments Stock Warrant [Text Block]	12. WARRANTS The following is a continuity schedule of the Company’s common share purchase warrants: Number of Warrants Weighted-Average Exercise Price ($) Outstanding and exercisable, March 31, 2015 10,823,450 1.35 Issued 7,225,625 1.35 Exercised (148,787 ) (0.80 ) Outstanding and exercisable, March 31, 2016 17,900,288 1.35 Exercised (262,045 ) (0.80 ) Outstanding and exercisable, March 31, 2017 17,638,243 1.35 Exercised (5,000,172 ) 0.25 Issued in connection with anti-dilution provision connected to warrant transaction 83,752 0.749 Issued in connection with anti-dilution provision connected to warrant transaction 941,191 1.2933 Issued in connection to the warrant transaction to the broker 400,014 0.25 Issued in connection with the conversion of loans and interest into common shares 16,006,322 0.0625 Issued in connection with the conversion of loans and interest into common shares 2,348,587 0.60 Issued in connection with anti-dilution provision connected to warrant transaction 20,458,058 0.4868 Issued in connection with anti-dilution provision connected to warrant transaction 2,019,583 0.2952 Outstanding at June 30, 2018 and March 31, 2018 54,895,578 0.3546 During the year ended March 31, 2018, the Company consummated an offer to amend and exercise its outstanding warrants, enabling the holders of the warrants to exercise such warrants for $0.25 per share. The Company received net proceeds of $1,125,038. The Company also converted loans and interest due. Due to an anti-dilution clause in the warrant agreement for such outstanding warrants, an additional 83,752 warrants were issued to the $0.80 warrant holders and 941,191 warrants were issued to the $1.40 warrant holders. Furthermore, as a result of the anti-dilution clause, the exercise price of the warrants changed from $0.80 to $0.7490 and from $1.40 to $1.2933. Due to the anti-dilution clause in the warrant agreements for such outstanding warrants, an additional 2,019,583 warrants were issued to the $0.7499 warrant holders and 20,458,058 warrants were issued to the $1.2933 warrant holders. Furthermore, as a result of the anti-dilution clause, the exercise price of the warrants changed from $0.749 to $0.2952 and from $1.2933 to $0.4868 as a result of the loan and interest conversion for shares that have been issued at March 31, 2018 and shares that were issued on June 12, 2018. The Company measured the effects of the above two transactions, which triggered anti-dilution clause using the binomial tree model and recorded a loss of $74,086 against the deficit for the year ended March 31, 2018. The Company issued 400,014 warrants at $0.25 for four years expiring June 27, 2020 to the firm who facilitated the warrant offer. The Company issued 2,348,587 warrants at $0.60 which expire in 5 years on March 31, 2023 and 16,006,322 warrants at $0.0625 which also expire March 31, 2023 in connection with the loan and interest conversion transaction. Common share purchase warrants The following is a summary of common share purchase warrants as of June 30, 2018: Exercise Price ($) Number of Warrants Expiry Date 0.60 2,348,587 March 31, 2023 0.4868 15,603,103 February 26, 2019 0.4868 3,265,093 March 27, 2019 0.4868 871,813 March 31, 2019 0.4868 6,759,081 April 21, 2019 0.4868 3,191,037 May 27,2019 0.4868 3,117,199 June 30, 2019 0.2952 3,333,328 February 26, 2019 0.25 400,014 June 27, 2020 0.0625 9,603,842 August 14, 2022 0.0625 6,402,481 March 31, 2022 54,895,578 The weighted-average remaining contractual term of the outstanding warrants was 2.01 (March 31, 2018 – 2.27). The exercise price and number of underlying shares with respect the $0.4868 and $0.2952 warrants are expected to be further adjusted pursuant to the anti-dilution provisions therein, as a result of any further common share issuances.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	13. COMMITMENTS AND CONTINGENCIES Contingencies From time to time, the Company may be involved in a variety of claims, suits, investigations and proceedings arising in the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although claims, suits, investigations and proceedings are inherently uncertain, and their results cannot be predicted with certainty, the Company believes that the resolution of current pending matters will not have a material adverse effect on its business, financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on the Company because of legal costs, diversion of management resources and other factors. Commitments (a) On February 25, 2015, 262,904 common shares were issued to two former lenders connected with a $241,185 loan received and repaid during fiscal 2013. The common shares were valued at $210,323 based on the value of the concurrent private placement and recorded in stock-based compensation on the consolidated statement of operations and comprehensive loss. As part of the consideration for the initial loan, the former Chief Technology Officer and the new Chief Technology Officer had transferred 314,560 common shares to the lenders. For contributing the common shares to the lenders, the Company intends to reimburse the former Chief Technology Officer and the new Chief Technology Officer 320,000 common shares collectively. As at June 30, 2018, these shares have not yet been issued. (b) In connection with the acquisition of IMT, the Company acquired a license agreement dated June 8, 2009, pursuant to which the Company pays the licensors an aggregate royalty of 1% of sales based on patent #8,613,691. No sales were made on the technology under this patent as it has not yet been commercialized. One of the licensors is a founder of IMT and a former officer and director of the Company. (c) On May 17, 2017, the Company entered into a Co-operative Joint Venture Contract (the “JV Contract”) with Ginger Capital Investment Holding, Ltd. (the “JV Partner”) to form a China-based joint venture to commercialize the Company’s products (“China JV”) in which the Company has a 25% interest and the JV Partner has a 75% interest. The China JV entity formally was created on May 22, 2018. Under the terms of the JV Contract, the JV Partner is required to contribute $290,000 within 30 days of formation, $435,000 12 months later and $725,000 60 months after the date of formation. The Company is required to contribute certain intellectual property to the China JV through a license. As of June 30, 2018, the JV Partner has not made the required $290,000 investment into the China JV. The China JV has entered into an office rent commitment in Tianjin, PRC for five years, for which the monthly rent payments expressed in USD are $10,083 for year one, $13,444 for year two and three and $14,141 for years four and five. An approximate $18,131 prepaid deposit was provided as part of the commitment. The operations of the China JV are currently financed by Bionik’s JV Partner and approximately $93,309 is due to them at June 30, 2018. Bionik is applying the equity method of accounting to determine the net income from the joint venture partnership. As of June 30, 2018, Bionik has not made any investments into the China JV. (d) On March 6, 2018, the Company signed a distribution agreement with Curexo Inc. for South Korea and as part of this agreement, the Company is obligated to buy a rehabilitative product from Curexo Inc. for $200,000 when this product is fully developed. It is not yet developed at June 30, 2018.

RISK MANAGEMENT

RISK MANAGEMENT	3 Months Ended
	Jun. 30, 2018
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	14. RISK MANAGEMENT The Company’s cash balances are maintained in a bank in Canada and a USA bank. Deposits held in banks in Canada are insured up to $100,000 CAD per depositor for each bank by The Canada Deposit Insurance Corporation, a federal crown corporation. Actual balances at times may exceed these limits. Interest Rate Risk Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in the interest rates. The Company has minimal exposure to fluctuations in the market interest rate. In seeking to minimize the risks from interest rate fluctuations, the Company manages exposure through its normal operating and financing activities. Liquidity Risk Liquidity risk is the risk that the Company will incur difficulties meeting its financial obligations, as they are due. The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due. Accounts payable and accrued liabilities are due within the current operating period. The Company has funded its operations through the issuance of capital stock, convertible debt and loans in addition to grants and investment tax credits received from the Government of Canada.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Events [Text Block]	15. SUBSEQUENT EVENTS Subsequent to June 30, 2018, the Company converted $4,732,853 of convertible loans and interest into 102,509,278 common shares in accordance with their terms. As at July 20, 2018, 102,509,278 of these common shares were issued. Due to an anti-dilution clause in warrant agreements for certain outstanding warrants, an additional 10,192,712 warrants were issued to the $0.4868 warrant holders and 945,710 warrants were issued to the $0.2952 warrant holders. Furthermore, as a result of the anti-dilution clause, the exercise price of the warrants changed from $0.4868 to $0.3714 and from $0.2952 to $0.2300 as a result of loan and interest conversion transaction for shares that have been issued as a result of the July 20, 2018 conversions described above.

SIGNIFICANT ACCOUNTING POLICI22

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Consolidated Financial Statements [Policy Text Block]	Unaudited Condensed Consolidated Interim Financial Statements These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements of the Company and should be read in conjunction with those annual audited financial statements filed on Form 10-K for the year ended March 31, 2018. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. This is the first set of the Company’s unaudited condensed consolidated interim financial statements where ASU-2014-09 “Revenue from Contracts with Customers (Topic 606)” has been applied. The changes in accounting policies from those used in the Company’s unaudited condensed consolidated interim financial statements from the quarter ended June 30, 2018 are described below. Impact on the 2018 unaudited condensed consolidated interim financial statements ASU-2014-09 had no impact on the Company’s unaudited condensed consolidated interim statement of loss and comprehensive loss for the three month period ended June 30, 2018.
Recently Adopted Accounting Pronouncements [Policy Text Block]	Newly Adopted and Recently Issued Accounting Pronouncements Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying condensed consolidated interim financial statements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). The updated standard will replace most existing revenue recognition guidance in U.S. GAAP. The new standard introduces a five-step process to be followed in determining the amount and timing of revenue recognition. It also provides guidance on accounting for costs incurred to obtain or fulfill contracts with customers, and establishes disclosure requirements which are more extensive than those required under existing U.S. GAAP. The FASB has issued numerous amendments to ASU 2014-09 from August 2015 through January 2018, which provide supplemental and clarifying guidance, as well as amend the effective date of the new standard. ASU 2014-09, as amended, is effective for the Company in the interim period ended June 30, 2018. The standard permits the use of either the retrospective or modified retrospective (cumulative effect) transition method. The Company adopted the modified retrospective transition method The Company has adopted ASU-2014-01 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. As a result of the adoption of ASU-2014-09, the Company’s accounting policies have been updated. See “Revenue Recognition” below for these changes in accounting policies, as well as new disclosure requirements. The changes in accounting policies will also be reflected in the Company’s unaudited condensed consolidated interim financials statements as at the quarter ended June 30, 2018.” In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes,” which require that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015-17 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU-2015-17 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The updates make several modifications to Subtopic 825-10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 2017. The Company has adopted ASU-2016-01 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASU 2016-02 will have on the consolidated financial position and the consolidated results of operations. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU-2016-15 for the fiscal year ending March 31, 2019 and it did not have material effect on the consolidated financial position and the consolidated results of operations. In January 2017, the FAS issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU2017-01 further states that when substantially all of the fair value of gross assets acquitted is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019. In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting (ASU 2107-9). The FASB issued the update to provide clarity and reduce the cost and complexity when applying guidance in Topic 718. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modifications accounting in Topic 718. ASU 2017-09 is effective for the Company in the interim period ended June 30, 2018. The Company has adopted ASU-2017-09 during the quarter ended June 30, 2018 and it did not have material effect on the consolidated financial position and the consolidated results of operations.
Inventory, Policy [Policy Text Block]	Inventory Inventory is stated at the lower of cost or net realizable value. Cost is recorded at standard cost, on the first-in, first-out basis. Work-in-progress and finished goods consist of materials, labor and allocated overhead.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company has adopted ASU-2014-09 with an initial application date of April 1, 2018. The updated accounting policies, the impact on the June 30, 2018 unaudited condensed consolidated interim financial statements and additional disclosures are detailed as follows: The Company determines revenue recognition through the following steps: a) identification of the contract with a customer; b) identification of the performance obligation in the contract; c) determination of the transaction price; d) allocation of the transaction price for the performance obligations in the contract; and e) recognition of revenue when the Company satisfies a performance obligation. Revenue is recognized when control of a product is transferred to a customer. Revenue is measured based on the consideration specified in a contract with a customer, net of returns and discounts. Accruals for sales returns are calculated based on the best estimate of the amount of product that will ultimately be returned by customers, reflecting historical experience and the magnitude of non-conforming inventory claims made by the customers that have either been approved or are pending review. Contract liabilities are recorded when cash payments are received or due in advance of the Company’s performance. In the comparative period, revenue was measured at the fair value of the consideration received or receivable, net of returns and discounts and was recognized when the risks and rewards of ownership has transferred to the customer. No revenue was recognized if there was significant uncertainties regarding recovery of the consideration due, the costs incurred or to be incurred could not be measured reliably, or there was continuing management involvement with the goods.
Standard Product Warranty, Policy [Policy Text Block]	Warranty Reserve and Deferred Warranty Revenue The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the balance sheet amounted to $75,065 and $64,957 at June 30, 2018 and March 31, 2018, respectively. The Company also sells extended warranties for additional periods beyond the standard warranty. Extended warranty revenue is deferred and recognized as revenue over the extended warranty period. The Company recognized $10,108 of expense related to the change in warranty reserves and warranty costs incurred and recorded as an expense in cost of goods sold during the three month period ended June 30, 2018 (June 30, 2017 $Nil).
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The estimates are based on management’s best knowledge of current events and actions of the Company it may undertake in the future. Significant areas requiring the use of estimates relate to the valuation of inventory, revenue recognition, the useful life of equipment and intangible assets, impairment of goodwill and intangible assets. Actual results could differ from these estimates.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs, which are as observable as possible, and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, due from related parties, demand loans, and convertible loans approximate fair value because of the short period of time between the origination of such instruments, their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company has recognized shares to be issued, stock options and warrants, for which it did not as of March 31, 2018 have sufficient authorized share capital to issue, as a liability that is measured at fair value based on Level 1 inputs, for the component related to shares to be issued, and Level 3 inputs for the measurement of the stock options and warrants using a valuation model, as disclosed in Notes 11 & 12. This was reversed in the quarter ended June 30, 2018, when the Company’s authorized capital was increased from 250,000,000 to 500,000,000 and gain on mark to market valuation of $2,048,697 was recognized. The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the quarter ended June 30, 2018.

CHANGE IN ACCOUNTING POLICY (Ta

CHANGE IN ACCOUNTING POLICY (Tables)	3 Months Ended
	Jun. 30, 2018
Disclosure Text Block [Abstract]
Schedule of Changes in Accounting Policy [Table Text Block]	The following financial statement line items for the periods indicated were affected by the change in accounting principle. Income statement Period ended June 30, 2017 As originally ‎ reported As adjusted Effect of change Sales $ 87,520 $ 87,520 $ - Cost of Sales 29,300 29,300 - Total operating expenses 2,127,589 2,127,589 - Total other expenses 175,953 171,149 (4,804 ) Net loss and comprehensive loss for the period (2,245,322 ) (2,240,518 ) 4,804 Statement of cash flows As at June 30 2017 As originally ‎ reported As adjusted Effect of change Net loss for period $ (2,245,322 ) $ (2,240,518 ) $ 4,804 Adjustment for items not affecting cash and changes in non-cash working capital items 938,665 933,861 (4,804 ) Net cash used in operating activities (1,306,657 ) (1,306,657 ) - Net cash used in investing activities (15,600 ) (15,600 ) - Net cash provided by financing activities 1,625,038 1,625,038 - Net increase in cash and cash equivalents for the period 302,781 302,781 - Cash and cash equivalents, beginning of period 543,650 543,650 - Cash and cash equivalents, end of period 846,431 846,431 -

TECHNOLOGY AND OTHER ASSETS (Ta

TECHNOLOGY AND OTHER ASSETS (Tables)	3 Months Ended
	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Business Acquisition, Pro Forma Information [Table Text Block]	The schedule below reflects the intangible assets acquired in the IMT acquisition on April 21, 2016 and the asset amortization period and expense for the three month period ended June 30, 2018 and the year ended March 31, 2018: Intangible Amortization Expense March Value at March Expense June Value at June assets acquired period (years) Value acquired 31, 2018 31, 2018 30, 2018 30, 2018 $ $ $ $ $ Patents and exclusive License 9.74 1,306,031 134,126 1,045,530 33,522 1,012,008 Trademark Indefinite 2,505,907 - 2,505,907 - 2,505,907 Customer relationships 10 1,431,680 143,206 1,153,543 35,792 1,117,751 Non-compete agreement 2 61,366 30,709 1,739 1,739 - Assembled Workforce 1 275,720 15,864 - - - 5,580,704 323,905 4,706,719 71,053 4,635,666

PREPAID EXPENSES AND OTHER RE25

PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)	3 Months Ended
	Jun. 30, 2018
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	June 30, 2018 March 31, 2018 $ $ Prepaid expenses and sundry receivables 73,987 86,957 Prepaid inventory 261,626 301,104 Prepaid insurance 136,113 36,497 Sales taxes receivable (i) 13,712 9,097 485,438 433,655 (i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES (Tables)

INVENTORIES (Tables)	3 Months Ended
	Jun. 30, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	June 30, 2018 March 31, 2018 $ $ Raw materials 124,795 237,443 Work in Progress 31,000 - 155,795 237,443

EQUIPMENT (Tables)

EQUIPMENT (Tables)	3 Months Ended
	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Equipment consisted of the following as at June 30, 2018 and March 31, 2018: June 30, 2018 March 31, 2018 Accumulated Accumulated Cost Depreciation Net Cost Depreciation Net $ $ $ $ $ $ Computers and electronics 264,349 227,977 36,372 256,505 223,750 32,755 Furniture and fixtures 36,795 28,481 8,314 36,795 28,051 8,744 Demonstration equipment 200,186 116,798 83,388 200,186 105,441 94,745 Manufacturing equipment 88,742 85,819 2,923 88,742 85,668 3,074 Tools and parts 11,422 6,020 5,402 11,422 5,741 5,681 Assets under capital lease 23,019 9,208 13,811 23,019 8,057 14,962 624,513 474,303 150,210 616,669 456,708 159,961

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	3 Months Ended
	Jun. 30, 2018
Convertible Debt [Table Text Block]	Balance, March 31, 2018 $ 51,479 Accrued interest 1,496 Repayment 52,975 Balance, June 30, 2018 $ -
Schedule of Convertible Debt Fair Value [Table Text Block]	At issuance Conversion feature fair value At June 30, 2018 Principal Beneficial conversion Anti-dilution Fair value of debt Accretion expense Interest Ending balance Convertible promissory note $ 2,965,971 $ 368,936 $ 1,042,632 $ 1,554,403 $ 134,251 $ 3,533 $ 1,692,187
Schedule of Convertible Debt Beneficial Conversion Feature Table text Block [Table Text Block]	Conversion feature fair value Beneficial conversion Anti-dilution Total At Issuance $ 368,936 $ 1,042,632 $ 1,411,568 Fair value adjustment 60,304 (16,217 ) 44,087 Ending balance at June 30, 2018 $ 429,240 $ 1,026,415 $ 1,455,655

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables)	3 Months Ended
	Jun. 30, 2018
Stockholders' Equity Note [Abstract]
Schedule of Stockholders Equity [Table Text Block]	June 30, 2018 March 31, 2018 Number of Number of shares $ shares $ Exchangeable Shares: Balance beginning of year 44,271,880 44,273 47,909,336 47,910 Converted into common shares (a) (3,000,000 ) (3,000 ) (3,637,456 ) (3,637 ) Balance at the end of period 41,271,880 41,273 44,271,880 44,273 Common Shares Balance at beginning of the period 205,328,106 205,326 48,885,107 48,884 Shares issued to exchangeable shares 3,000,000 3,000 3,637,456 3,637 Shares issued on conversion of loans (b) 39,545,776 39,546 147,805,371 147,805 Warrants exercised - - 5,000,172 5,000 Balance at end of the period 247,873,882 247,872 205,328,106 205,326 TOTAL SHARES 289,145,762 289,145 249,599,986 249,599 a. During the three month period ended June 30, 2018, 3,000,000 exchangeable shares were exchanged on a 1 for 1 basis in accordance with their terms. (March 31, 2018 – 3,637,456). b. During the three month period ended June 30, 2018, 39,545,776 shares of common stock were issued once the Company increased its authorized shares of common stock from 250,000,000 to 500,000,000. These shares relate to convertible loans and interest that converted on March 31, 2018 and were recorded as a liability on March 31, 2018 until the shares were issued on June 12, 2018. The liability was reclassified at June 12, 2018 into equity by recording the original value of $2,470,622 of the shares to be issued, as well as the fair value of options and warrants at June 12, 2018 net of fair value of options issued in the period ended June 12, 2018 of $1,173,534, which was charged to equity and a $2,048,697 gain on the fair value reevaluation was recognized as other income in the Statement of Operations and Comprehensive Loss.

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	3 Months Ended
	Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation, Performance Shares Award Outstanding Activity [Table Text Block]	The following is a summary of stock options outstanding and exercisable as of June 30, 2018: Exercise Price ($) Number of Options Expiry Date Exercisable Options 0.165 154,134 April 1, 2021 154,134 0.23 94,368 June 20, 2021 94,368 0.23 1,981,728 July 1, 2021 1,981,728 0.23 141,557 February 17, 2022 141,557 1.22 400,000 November 24, 2022 266,667 1.00 1,936,667 December 14, 2022 1,633,333 0.95 111,937 March 28, 2023 111,937 1.05 433,027 March 28, 2023 433,027 1.00 250,000 April 26, 2023 166,667 1.00 250,000 August 8, 2023 250,000 0.70 400,000 February 6, 2024 133,333 0.68 250,000 February 13, 2024 250,000 0.95 31,620 March 3, 2024 31,620 1.05 122,324 March 3, 2024 122,324 0.95 6,324 March 14, 2024 6,324 1.05 24,465 March 14,2024 24,465 0.95 72,727 September 30, 2024 72,727 1.05 281,345 September 30, 2024 281,345 0.95 3,478 June 2, 2025 3,478 1.05 13,456 June 2, 2025 13,456 0.25 66,298 December 30, 2025 66,298 0.95 49,160 December 30, 2025 27,261 0.161 12,215,354 September 1, 2027 2,035,892 0.155 3,365,000 January 24, 2025 - 0.0649 6,000,000 April 19, 2028 6,000,000 0.0462 750,000 June 10, 2025 - 29,404,696 14,301,941

WARRANTS (Tables)

WARRANTS (Tables)	3 Months Ended
	Jun. 30, 2018
Warrants and Rights Note Disclosure [Abstract]
Schedule Of Share Based Compensation Stock Purchase Warrants Activity [Table Text Block]	The following is a continuity schedule of the Company’s common share purchase warrants: Number of Warrants Weighted-Average Exercise Price ($) Outstanding and exercisable, March 31, 2015 10,823,450 1.35 Issued 7,225,625 1.35 Exercised (148,787 ) (0.80 ) Outstanding and exercisable, March 31, 2016 17,900,288 1.35 Exercised (262,045 ) (0.80 ) Outstanding and exercisable, March 31, 2017 17,638,243 1.35 Exercised (5,000,172 ) 0.25 Issued in connection with anti-dilution provision connected to warrant transaction 83,752 0.749 Issued in connection with anti-dilution provision connected to warrant transaction 941,191 1.2933 Issued in connection to the warrant transaction to the broker 400,014 0.25 Issued in connection with the conversion of loans and interest into common shares 16,006,322 0.0625 Issued in connection with the conversion of loans and interest into common shares 2,348,587 0.60 Issued in connection with anti-dilution provision connected to warrant transaction 20,458,058 0.4868 Issued in connection with anti-dilution provision connected to warrant transaction 2,019,583 0.2952 Outstanding at June 30, 2018 and March 31, 2018 54,895,578 0.3546
Schedule of Common Share Purchase Warrants Outstanding [Table Text Block]	The following is a summary of common share purchase warrants as of June 30, 2018: Exercise Price ($) Number of Warrants Expiry Date 0.60 2,348,587 March 31, 2023 0.4868 15,603,103 February 26, 2019 0.4868 3,265,093 March 27, 2019 0.4868 871,813 March 31, 2019 0.4868 6,759,081 April 21, 2019 0.4868 3,191,037 May 27,2019 0.4868 3,117,199 June 30, 2019 0.2952 3,333,328 February 26, 2019 0.25 400,014 June 27, 2020 0.0625 9,603,842 August 14, 2022 0.0625 6,402,481 March 31, 2022 54,895,578

NATURE OF OPERATIONS (Details T

NATURE OF OPERATIONS (Details Textual) - USD ($)	1 Months Ended		3 Months Ended
	Apr. 21, 2016	Feb. 26, 2015	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2014
Working Capital Surplus (Deficit)			$ 3,152,267		$ 6,711,941
Comprehensive Income (Loss), Net of Tax, Attributable to Parent			$ (760,698)	$ (2,240,518)
Common Stock, Shares Authorized			500,000,000		250,000,000	150,000,000	200,000,000
Retained Earnings (Accumulated Deficit)			$ (36,537,038)		$ (35,776,340)
Interactive Motion Technologies, Inc. [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	23,650,000
Share Exchange Agreement [Member]
Stock Issued During Period, Shares, New Issues		50,000,000
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage		100.00%

CHANGE IN ACCOUNTING POLICY (De

CHANGE IN ACCOUNTING POLICY (Details) - USD ($)	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Sales	$ 501,333	$ 87,520
Cost of Sales	253,163	29,300
Total operating expenses	2,882,941	2,127,589
Total other expenses	(1,874,073)	171,149
Net loss and comprehensive loss for the period	$ (760,698)	(2,240,518)
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Sales		87,520
Cost of Sales		29,300
Total operating expenses		2,127,589
Total other expenses		175,953
Net loss and comprehensive loss for the period		(2,245,322)
Scenario, Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Sales		0
Cost of Sales		0
Total operating expenses		0
Total other expenses		(4,804)
Net loss and comprehensive loss for the period		$ 4,804

CHANGE IN ACCOUNTING POLICY (34

CHANGE IN ACCOUNTING POLICY (Details 1) - USD ($)	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net loss for period	$ (760,698)	$ (2,240,518)
Adjustment for items not affecting cash and changes in non-cash working capital items		933,861
Net cash used in operating activities	(2,421,086)	(1,306,657)
Net cash used in investing activities	(7,844)	(15,600)
Net cash provided by financing activities	2,881,323	1,625,038
Net increase in cash and cash equivalents for the period	452,393	302,781
Cash and cash equivalents, beginning of period	507,311	543,650
Cash and cash equivalents, end of period	$ 959,704	846,431
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net loss for period		(2,245,322)
Adjustment for items not affecting cash and changes in non-cash working capital items		938,665
Net cash used in operating activities		(1,306,657)
Net cash used in investing activities		(15,600)
Net cash provided by financing activities		1,625,038
Net increase in cash and cash equivalents for the period		302,781
Cash and cash equivalents, beginning of period		543,650
Cash and cash equivalents, end of period		846,431
Scenario, Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net loss for period		4,804
Adjustment for items not affecting cash and changes in non-cash working capital items		(4,804)
Net cash used in operating activities		0
Net cash used in investing activities		0
Net cash provided by financing activities		0
Net increase in cash and cash equivalents for the period		0
Cash and cash equivalents, beginning of period		0
Cash and cash equivalents, end of period		$ 0

SIGNIFICANT ACCOUNTING POLICI35

SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($)	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2014
Significant Accounting Policies [Line Items]
Standard and Extended Product Warranty Accrual	$ 75,065		$ 64,957
Product Warranty Expense	$ 10,108	$ 0
Common Stock, Shares Authorized	500,000,000		250,000,000	150,000,000	200,000,000
Loss on Mark to Market Reevaluation	$ (2,048,697)	$ 0

TECHNOLOGY AND OTHER ASSETS (De

TECHNOLOGY AND OTHER ASSETS (Details) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Apr. 21, 2016	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 5,580,704
Amortization of Intangible Assets		$ 71,053	$ 92,949	$ 323,905
Intangible Assets, Net (Excluding Goodwill)		4,635,666		4,706,719
Patents and exclusive License Agreement [Member]
Finite-Lived Intangible Asset, Useful Life	9 years 8 months 26 days
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 1,306,031
Amortization of Intangible Assets		33,522		134,126
Intangible Assets, Net (Excluding Goodwill)		1,012,008		1,045,530
Trademark [Member]
Finite Lived Intangible Asset Useful Life Description	Indefinite
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 2,505,907
Amortization of Intangible Assets		0		0
Intangible Assets, Net (Excluding Goodwill)		2,505,907		2,505,907
Customer relationships [Member]
Finite-Lived Intangible Asset, Useful Life	10 years
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 1,431,680
Amortization of Intangible Assets		35,792		143,206
Intangible Assets, Net (Excluding Goodwill)		1,117,751		1,153,543
Non compete agreement [Member]
Finite-Lived Intangible Asset, Useful Life	2 years
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 61,366
Amortization of Intangible Assets		1,739		30,709
Intangible Assets, Net (Excluding Goodwill)		0		1,739
Assembled Workforce [Member]
Finite-Lived Intangible Asset, Useful Life	1 year
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 275,720
Amortization of Intangible Assets		0		15,864
Intangible Assets, Net (Excluding Goodwill)		$ 0		$ 0

TECHNOLOGY AND OTHER ASSETS (37

TECHNOLOGY AND OTHER ASSETS (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018
Amortization of Intangible Assets	$ 71,053	$ 92,949	$ 323,905

PREPAID EXPENSES AND OTHER RE38

PREPAID EXPENSES AND OTHER RECEIVABLES (Details) - USD ($)		Jun. 30, 2018	Mar. 31, 2018
Prepaid Expense And Other Receivables [Line Items]
Prepaid expenses and sundry receivables		$ 73,987	$ 86,957
Prepaid inventory		261,626	301,104
Prepaid insurance		136,113	36,497
Sales taxes receivable	[1]	13,712	9,097
Prepaid Expense and Other Receivables		$ 485,438	$ 433,655
[1]	Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES (Details)

INVENTORIES (Details) - USD ($)	Jun. 30, 2018	Mar. 31, 2018
Inventory [Line Items]
Raw materials	$ 124,795	$ 237,443
Work in Progress	31,000	0
Inventory, Net	$ 155,795	$ 237,443

INVENTORIES (Details Textual)

INVENTORIES (Details Textual) - USD ($)	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cost of Goods and Services Sold	$ 253,163	$ 29,300
Inventory Cost [Member]
Cost of Goods and Services Sold	$ 237,000	$ 29,300

EQUIPMENT (Details)

EQUIPMENT (Details) - USD ($)	Jun. 30, 2018	Mar. 31, 2018
Equipment [Line Items]
Equipment, Cost	$ 624,513	$ 616,669
Accumulated Depreciation	474,303	456,708
Equipment, Net	150,210	159,961
Computers and electronics [Member]
Equipment [Line Items]
Equipment, Cost	264,349	256,505
Accumulated Depreciation	227,977	223,750
Equipment, Net	36,372	32,755
Furniture and fixtures [Member]
Equipment [Line Items]
Equipment, Cost	36,795	36,795
Accumulated Depreciation	28,481	28,051
Equipment, Net	8,314	8,744
Demonstration equipment [Member]
Equipment [Line Items]
Equipment, Cost	200,186	200,186
Accumulated Depreciation	116,798	105,441
Equipment, Net	83,388	94,745
Manufacturing equipment [Member]
Equipment [Line Items]
Equipment, Cost	88,742	88,742
Accumulated Depreciation	85,819	85,668
Equipment, Net	2,923	3,074
Tools and parts [Member]
Equipment [Line Items]
Equipment, Cost	11,422	11,422
Accumulated Depreciation	6,020	5,741
Equipment, Net	5,402	5,681
Assets under capital lease [Member]
Equipment [Line Items]
Equipment, Cost	23,019	23,019
Accumulated Depreciation	9,208	8,057
Equipment, Net	$ 13,811	$ 14,962

EQUIPMENT (Details Textual)

EQUIPMENT (Details Textual) - USD ($)	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Equipment [Line Items]
Depreciation	$ 17,595	$ 24,552

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - Demand Notes payable [Member]	3 Months Ended
	Jun. 30, 2018USD ($)
Balance	$ 51,479
Accrued interest	1,496
Repayment	52,975
Balance	$ 0

NOTES PAYABLE (Details 1)

NOTES PAYABLE (Details 1) - USD ($)	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Accretion Expense	$ 134,251	$ 0
Convertible Debt [Member]
Principal	2,965,971
Beneficial conversion	368,936
Anti-dilution	1,042,632
Fair value of debt	1,554,403
Accretion Expense	134,251
Interest	3,533
Convertible Notes Payable, Noncurrent	$ 1,692,187

NOTES PAYABLE (Details 2)

NOTES PAYABLE (Details 2) - Convertible Debt [Member]	3 Months Ended
	Jun. 30, 2018USD ($)
At Issuance	$ 1,411,568
Fair value adjustment	44,087
Ending balance at June 30, 2018	1,455,655
Beneficial conversion [Member]
At Issuance	368,936
Fair value adjustment	60,304
Ending balance at June 30, 2018	429,240
Antidilution [Member]
At Issuance	1,042,632
Fair value adjustment	(16,217)
Ending balance at June 30, 2018	$ 1,026,415

NOTES PAYABLE (Details Textual)

NOTES PAYABLE (Details Textual) - USD ($)	3 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jul. 20, 2018	Mar. 31, 2018
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.00%
Short-term Debt	$ 0			$ 51,479
Proceeds from Related Party Debt	2,291,930
Proceeds from Convertible Debt	2,934,298	$ 500,000
Discount on Convertible Loans			10.00%
Interest Costs Capitalized	31,673
Accretion Expense	134,251	0
Convertible Loans Payable [Member]
Debt Instrument [Line Items]
Accretion Expense	134,251	0
Debt Instrument Convertible Conversion feature Fair Value Adjustments	44,087	0
IMT Notes [Member]
Debt Instrument [Line Items]
Interest Expense, Debt		$ 2,341
Demand Notes payable [Member]
Debt Instrument [Line Items]
Interest Expense, Debt	$ 1,496

RELATED PARTY TRANSACTIONS AN47

RELATED PARTY TRANSACTIONS AND BALANCES (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018
Related Party Transaction [Line Items]
Accrued interest receivable	$ 59	$ 707
Related Party Transaction, Rate	1.00%
Chief Operating Officer [Member]
Related Party Transaction [Line Items]
Due from Related Parties	$ 18,547	18,897
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	1,957	208,567
Chief Technology Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	1,643	135,039
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	$ 920	$ 116,624

SHARE CAPITAL (Details)

SHARE CAPITAL (Details) - USD ($)		3 Months Ended			9 Months Ended	12 Months Ended
		Jun. 30, 2018		Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2018
Opening Balance		$ 20,463,014		$ 24,150,650	$ 23,491,008	$ 24,150,650
Shares issued to exchangeable shares		2,470,622			9,180,785
Warrants exercised				1,125,038
Closing Balance		$ 23,941,884		$ 23,491,008	$ 20,463,014	$ 20,463,014
Exchangable Shares [Member]
Opening Balance (in shares)		44,271,880		47,909,336		47,909,336
Opening Balance		$ 44,273		$ 47,910		$ 47,910
Converted into common shares (in shares)		(3,000,000)	[1]			(3,637,456)
Converted into common shares		$ (3,000)	[1]			$ (3,637)
Closing Balance (in shares)		41,271,880			44,271,880	44,271,880
Closing Balance		$ 41,273			$ 44,273	$ 44,273
Common Shares [Member]
Opening Balance (in shares)		205,328,106		48,885,107		48,885,107
Opening Balance		$ 205,326		$ 48,884		$ 48,884
Shares issued to exchangeable shares (in shares)		3,000,000				3,637,456
Shares issued to exchangeable shares		$ 3,000				$ 3,637
Shares issued on conversion of loans (in shares)	[2]	39,545,776				147,805,371
Shares issued on conversion of loans	[2]	$ 39,546				$ 147,805
Warrants exercised (in shares)		0				5,000,172
Warrants exercised		$ 0				$ 5,000
Closing Balance (in shares)		247,873,882			205,328,106	205,328,106
Closing Balance		$ 247,872			$ 205,326	$ 205,326
Common Shares And Exchangeable Shares [Member]
Opening Balance (in shares)		249,599,986
Opening Balance		$ 249,599
Closing Balance (in shares)		289,145,762			249,599,986	249,599,986
Closing Balance		$ 289,145			$ 249,599	$ 249,599
[1]	During the three month period ended June 30, 2018, 3,000,000 exchangeable shares were exchanged on a 1 for 1 basis in accordance with their terms. (March 31, 2018 – 3,637,456).
[2]	During the three month period ended June 30, 2018, 39,545,776 shares of common stock were issued once the Company increased its authorized shares of common stock from 250,000,000 to 500,000,000. These shares relate to convertible loans and interest that converted on March 31, 2018 and were recorded as a liability on March 31, 2018 until the shares were issued on June 12, 2018. The liability was reclassified at June 12, 2018 into equity by recording the original value of $2,470,622 of the shares to be issued, as well as the fair value of options and warrants at June 12, 2018 net of fair value of options issued in the period ended June 12, 2018 of $1,173,534, which was charged to equity and a $2,048,697 gain on the fair value reevaluation was recognized as other income in the Statement of Operations and Comprehensive Loss.

SHARE CAPITAL (Details Textual)

SHARE CAPITAL (Details Textual) - USD ($)	3 Months Ended			9 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2014
Loss on Mark to Market Reevaluation	$ (2,048,697)		$ 0
Stock Issued During Period, Shares, Exchangeable Shares Excercised	3,000,000	3,637,456
Common Stock, Shares Authorized	500,000,000	250,000,000		250,000,000	150,000,000	200,000,000
Stock Issued During Period, Value, Conversion of Convertible Securities	$ 2,470,622			$ 9,180,785
Adjustments to Additional Paid in Capital, Stock Option and Warrant Reclassification	$ 1,173,534			$ (2,845,557)
Preferred Stock, Voting Rights	the Company issued one share of the Special Voting Preferred Stock, par value $0.001 per share
Common Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities	39,545,776			147,805,371
Stock Issued During Period, Value, Conversion of Convertible Securities	$ 39,546			$ 147,805
Adjustments to Additional Paid in Capital, Stock Option and Warrant Reclassification	$ 0			$ 0

STOCK OPTIONS (Details)

STOCK OPTIONS (Details)	3 Months Ended
	Jun. 30, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	29,404,696
Number of Exercisable Options	14,301,941
Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.165
Number of Options	154,134
Expiry Date	Apr. 1, 2021
Number of Exercisable Options	154,134
Stock Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.23
Number of Options	94,368
Expiry Date	Jun. 20, 2021
Number of Exercisable Options	94,368
Stock Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.23
Number of Options	1,981,728
Expiry Date	Jul. 1, 2021
Number of Exercisable Options	1,981,728
Stock Option Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.23
Number of Options	141,557
Expiry Date	Feb. 17, 2022
Number of Exercisable Options	141,557
Stock Option Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.22
Number of Options	400,000
Expiry Date	Nov. 24, 2022
Number of Exercisable Options	266,667
Stock Option Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1
Number of Options	1,936,667
Expiry Date	Dec. 14, 2022
Number of Exercisable Options	1,633,333
Stock Option Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.95
Number of Options	111,937
Expiry Date	Mar. 28, 2023
Number of Exercisable Options	111,937
Stock Option Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.05
Number of Options	433,027
Expiry Date	Mar. 28, 2023
Number of Exercisable Options	433,027
Stock Option Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1
Number of Options	250,000
Expiry Date	Apr. 26, 2023
Number of Exercisable Options	166,667
Stock Option Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1
Number of Options	250,000
Expiry Date	Aug. 8, 2023
Number of Exercisable Options	250,000
Stock Option Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.70
Number of Options	400,000
Expiry Date	Feb. 6, 2024
Number of Exercisable Options	133,333
Stock Option Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.68
Number of Options	250,000
Expiry Date	Feb. 13, 2024
Number of Exercisable Options	250,000
Stock Option Thirteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.95
Number of Options	31,620
Expiry Date	Mar. 3, 2024
Number of Exercisable Options	31,620
Stock Option Fourteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.05
Number of Options	122,324
Expiry Date	Mar. 3, 2024
Number of Exercisable Options	122,324
Stock Option Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.95
Number of Options	6,324
Expiry Date	Mar. 14, 2024
Number of Exercisable Options	6,324
Stock Option Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.05
Number of Options	24,465
Expiry Date	Mar. 14, 2024
Number of Exercisable Options	24,465
Stock Option Seventeen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.95
Number of Options	72,727
Expiry Date	Sep. 30, 2024
Number of Exercisable Options	72,727
Stock Option Eighteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.05
Number of Options	281,345
Expiry Date	Sep. 30, 2024
Number of Exercisable Options	281,345
Stock Option Nineteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.95
Number of Options	3,478
Expiry Date	Jun. 2, 2025
Number of Exercisable Options	3,478
Stock Option Twenty [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.05
Number of Options	13,456
Expiry Date	Jun. 2, 2025
Number of Exercisable Options	13,456
Stock Option Twenty One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.25
Number of Options	66,298
Expiry Date	Dec. 30, 2025
Number of Exercisable Options	66,298
Stock Option Twenty Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.95
Number of Options	49,160
Expiry Date	Dec. 30, 2025
Number of Exercisable Options	27,261
Stock Option Twenty Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.161
Number of Options	12,215,354
Expiry Date	Sep. 1, 2027
Number of Exercisable Options	2,035,892
Stock Option Twenty Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.155
Number of Options	3,365,000
Expiry Date	Jan. 24, 2025
Number of Exercisable Options	0
Stock Option Twenty Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.0649
Number of Options	6,000,000
Expiry Date	Apr. 19, 2028
Number of Exercisable Options	6,000,000
Stock Option Twenty Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.0462
Number of Options	750,000
Expiry Date	Jun. 10, 2025
Number of Exercisable Options	0

STOCK OPTIONS (Details Textual)

STOCK OPTIONS (Details Textual) - USD ($)

Jun. 11, 2018

Sep. 01, 2017

Aug. 03, 2017

Feb. 06, 2017

Aug. 08, 2016

Dec. 14, 2015

Apr. 20, 2018

Jan. 24, 2018

Feb. 13, 2017

Apr. 26, 2016

Apr. 21, 2016

Nov. 24, 2015

Jun. 30, 2018

Mar. 31, 2018

Jun. 30, 2017

Mar. 31, 2018

Mar. 31, 2017

Mar. 31, 2016

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

29,404,696

Allocated Share-based Compensation Expense

$ 562

$ 39,703

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term

7 years 10 months 20 days

5 years 9 months 22 days

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

7 years 4 months 17 days

5 years 8 months 12 days

Fair Value Of Options

$ 30,341

$ 1,260,437

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

Of such options, 2,035,892 have vested and 50% of the remaining options vest on performance goals being met and 50% vest over 5 years.

Exercise Price Range One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

1,000,000

Exercise Price Range Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.70

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

1,000,000

Exercise Price Range Three [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

1,000,000

Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated Share-based Compensation Expense

$ 595,412

$ 251,048

Employees of Bionik Inc [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 1

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

500,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

3,895,000

Allocated Share-based Compensation Expense

$ 2,582,890

17,813

17,813

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

250,000

3,000,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value

$ 213,750

Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period

250,000

Employees of Bionik Inc [Member] | Exercise Price Range One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.25

Employees of Bionik Inc [Member] | Exercise Price Range Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

0.95

Employees of Bionik Inc [Member] | Exercise Price Range Three [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 1.05

Employees of Bionik Inc [Member] | Unvested option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated Share-based Compensation Expense

10,169

Allocated Share-based Compensation Expense, Net of Tax

$ 0

Employees [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

3,640,000

650,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

250,000

Allocated Share-based Compensation Expense

35,609

35,609

Fair Value Of Options

$ 491,036

$ 694,384

Employee One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 1

Allocated Share-based Compensation Expense

18,113

54,339

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

750,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value

$ 652,068

Director and Employees and Consultant One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

2,495,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

436,667

40,000

25,000

Allocated Share-based Compensation Expense

41,350

100,289

Employee Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated Share-based Compensation Expense

20,433

20,433

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

400,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value

$ 245,200

Consultant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.68

Allocated Share-based Compensation Expense

$ 148,750

12,396

$ 12,396

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

250,000

Executive Employee [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

500,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.21

Allocated Share-based Compensation Expense

7,546

Fair Value Of Options

$ 387,209

Share Based Compensation Arrangement By Share Based Payment Award Additional Options Grants In Period Gross

1,500,000

Executive Employee And Consultant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

12,215,354

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.161

Allocated Share-based Compensation Expense

38,173

Fair Value Of Options

$ 1,832,304

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

5 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

2,035,892

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

50% of the remaining options vest on performance goals being met and 50% vest over 5 years.

New Executive Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

750,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.0462

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

7 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

114.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.59%

Executive Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

6,000,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.0649

Allocated Share-based Compensation Expense

$ 363,714

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

10 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

114.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.59%

Employees vest equally on January 24, 2019 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.155

Employees vest equally on January 24 2020 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

0.155

Employees vest equally on January 24 2021 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.155

WARRANTS (Details)

WARRANTS (Details) - $ / shares	3 Months Ended	12 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Number of Warrants, Outstanding and exercisable, Beginning balance	54,895,578	17,638,243	17,900,288	10,823,450
Number of Warrants, Issued				7,225,625
Number of Warrants, Exercised		(5,000,172)	(262,045)	(148,787)
Number of Warrants, Outstanding and exercisable, Ending balance	54,895,578	54,895,578	17,638,243	17,900,288
Weighted-Average Exercise Price, Outstanding and exercisable, Beginning balance	$ 0.3546	$ 1.35	$ 1.35	$ 1.35
Weighted-Average Exercise Price, Issued				1.35
Weighted-Average Exercise Price, Exercised		0.25	(0.80)	(0.80)
Weighted-Average Exercise Price, Outstanding and exercisable, Ending balance	$ 0.3546	$ 0.3546	$ 1.35	$ 1.35
Broker [Member]
Number of Warrants, Issued		400,014
Weighted-Average Exercise Price, Issued		$ 0.25
Warrant One [Member]
Number of Warrants, Issued		83,752
Weighted-Average Exercise Price, Issued		$ 0.749
Warrant Two [Member]
Number of Warrants, Issued		941,191
Weighted-Average Exercise Price, Issued		$ 1.2933
Common Shares One [Member]
Number of Warrants, Issued		16,006,322
Weighted-Average Exercise Price, Issued		$ 0.0625
Common Shares Two [Member]
Number of Warrants, Issued		2,348,587
Weighted-Average Exercise Price, Issued		$ 0.60
Common Shares Three [Member]
Number of Warrants, Issued		20,458,058
Weighted-Average Exercise Price, Issued		$ 0.4868
Common Shares Four [Member]
Number of Warrants, Issued		2,019,583
Weighted-Average Exercise Price, Issued		$ 0.2952

WARRANTS (Details 1)

WARRANTS (Details 1) - $ / shares	3 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.3546	$ 0.3546	$ 1.35	$ 1.35	$ 1.35
Class of Warrant or Right, Number of Warrants	54,895,578
Warrant One [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.60
Class of Warrant or Right, Number of Warrants	2,348,587
Class Of Warrant Or Right Expiry Date	Mar. 31, 2023
Warrant Two [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.4868
Class of Warrant or Right, Number of Warrants	15,603,103
Class Of Warrant Or Right Expiry Date	Feb. 26, 2019
Warrant Three [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.4868
Class of Warrant or Right, Number of Warrants	3,265,093
Class Of Warrant Or Right Expiry Date	Mar. 27, 2019
Warrant Four [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.4868	$ 0.4868
Class of Warrant or Right, Number of Warrants	871,813
Class Of Warrant Or Right Expiry Date	Mar. 31, 2019
Warrant Five [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.4868
Class of Warrant or Right, Number of Warrants	6,759,081
Class Of Warrant Or Right Expiry Date	Apr. 21, 2019
Warrant Six [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.4868
Class of Warrant or Right, Number of Warrants	3,191,037
Class Of Warrant Or Right Expiry Date	May 27, 2019
Warrant Seven [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.4868
Class of Warrant or Right, Number of Warrants	3,117,199
Class Of Warrant Or Right Expiry Date	Jun. 30, 2019
Warrant Eight [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.2952
Class of Warrant or Right, Number of Warrants	3,333,328
Class Of Warrant Or Right Expiry Date	Feb. 26, 2019
Warrant Nine [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.25
Class of Warrant or Right, Number of Warrants	400,014
Class Of Warrant Or Right Expiry Date	Jun. 27, 2020
Warrant Ten [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.0625
Class of Warrant or Right, Number of Warrants	9,603,842
Class Of Warrant Or Right Expiry Date	Aug. 14, 2022
Warrant Eleven [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.0625
Class of Warrant or Right, Number of Warrants	6,402,481
Class Of Warrant Or Right Expiry Date	Mar. 31, 2022

WARRANTS (Details Textual)

WARRANTS (Details Textual) - USD ($)	3 Months Ended		9 Months Ended	12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Mar. 31, 2018	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016	Mar. 31, 2015
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price	$ 0.3546		$ 0.3546	$ 0.3546	$ 1.35	$ 1.35	$ 1.35
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms	2 years 4 days			2 years 3 months 7 days
Proceeds from Warrant Exercises	$ 0	$ 1,125,038
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted						7,225,625
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price				$ (0.25)	$ 0.80	$ 0.80
Adjustment To Additional Paid In Capital Warrant Down Feature			$ 0
Warrant One [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price			$ 0.25	$ 0.25
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted				83,752
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price				$ 0.7490
Warrants Issued				400,014
Class of Warrant or Right Expiration Date				Jun. 27, 2020
Warrant One [Member] | Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price				$ 0.80
Warrant Two [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted				941,191
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price				$ 1.2933
Warrant Two [Member] | Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price				$ 1.40
Warrant Three [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price	0.4868
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted				2,019,583
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price				$ 0.2952
Warrant Three [Member] | Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price				0.749
Warrant Four [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price	0.4868		0.4868	$ 0.4868
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted				20,458,058
Common Shares One [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price			0.60	$ 0.60
Warrants Issued				2,348,587
Class of Warrant or Right Expiration Date				Mar. 31, 2023
Class of Warrant or Right Expiration years				5 years
Common Shares Two [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price			$ 0.0625	$ 0.0625
Warrants Issued				16,006,322
Class of Warrant or Right Expiration Date				Mar. 31, 2023
Retained Earnings [Member]
Class of Warrant or Right [Line Items]
Adjustment To Additional Paid In Capital Warrant Down Feature			$ (74,086)
Warrant [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price	$ 0.2952
Warrant Solicitation [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price			$ 0.25	$ 0.25

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($)	Mar. 06, 2018	May 17, 2017	Feb. 25, 2015	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation				$ 595,412	$ 251,048
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		25.00%
Description Of Contribution For Formation		Under the terms of the JV Contract, the JV Partner is required to contribute $290,000 within 30 days of formation, $435,000 12 months later and $725,000 60 months after the date of formation. The Company is required to contribute certain intellectual property to the China JV through a license.
Purchase Commitment, Description	On March 6, 2018, the Company signed a distribution agreement with Curexo Inc. for South Korea and as part of this agreement, the Company is obligated to buy a rehabilitative product from Curexo Inc. for $200,000 when this product is fully developed. It is not yet developed at June 30, 2018.
Noncontrolling Interest, Ownership Percentage by Parent		75.00%
Royalty on Sales,Percentage				1.00%
Operating Leases, Future Minimum Payments Due, Next Twelve Months				$ 10,083
Operating Leases, Future Minimum Payments, Due in Two Years				13,444
Operating Leases, Future Minimum Payments, Due in Three Years				13,444
Operating Leases, Future Minimum Payments, Due in Four Years				14,141
Operating Leases, Future Minimum Payments, Due in Five Years				14,141
Prepaid Deposits				18,131
Bioniks JV Partner [Member]
Due to Related Parties, Current				$ 93,309
Exchangable Shares [Member]
Stock Issued During Period, Shares, Issued for Services			262,904
Stock Transferred To Lenders			314,560
Stock to be Reimbursed to Officers			320,000
Stock Issued During Period, Value, Issued for Services			$ 241,185
Share-based Compensation			$ 210,323

RISK MANAGEMENT (Details Textua

RISK MANAGEMENT (Details Textual)	Jun. 30, 2018CAD ($)
Canada [Member] | Maximum [Member]
Concentration Risk [Line Items]
Cash, FDIC Insured Amount	$ 100,000

SUBSEQUENT EVENTS (Details Text

SUBSEQUENT EVENTS (Details Textual) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Jul. 20, 2018	Jun. 30, 2018	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2016
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted					7,225,625
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price			$ (0.25)	$ 0.80	$ 0.80
Warrant One [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted	10,192,712
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price	$ 0.4868
Warrant Two [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted	945,710
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price	$ 0.2952
Subsequent Event [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Shares to be Issued	102,509,278
Debt Conversion, Original Debt, Amount	$ 4,732,853
Debt Conversion, Converted Instrument, Shares Issued	102,509,278
Subsequent Event [Member] | Warrant One [Member]
Subsequent Event [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price	$ 0.3714
Subsequent Event [Member] | Warrant Two [Member]
Subsequent Event [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price	$ 0.2300